Devices like CGMs and AI-based platforms provide real-time insights and improve treatment decisions, reducing complications and enhancing patient engagement
The FDA does not verify the safety, effectiveness, or quality of compounded medications before marketing
Retatrutide is a specific, synthetic molecule engineered to activate three known hormone receptors: GLP-1, GIP, and glucagon
[17] [16] Importantly, patients without baseline retinopathy did not demonstrate increased risk, and the overall cardiovascular benefits of semaglutide were maintained despite this ocular safety signal
In the broader market, GLP-1 single-agonist formulations are commonly associated with semaglutide, the active ingredient in brand-name Wegovy, which is FDA-approved for chronic weight management